Tarveda Therapeutics Appoints Biotech Business Veteran Michael A. Metzger to Board of Directors

Therapeutics, Inc.
, a clinical-stage biopharmaceutical company
discovering and developing Pentarins™ as a new class of potent and
selective cancer medicines, today announced the appointment of Michael
A. Metzger to the company’s Board of Directors. Mr. Metzger has more
than 20 years of experience leading value-creating corporate
development, strategic and financial transactions and operating
biotechnology companies. Currently Mr. Metzger serves as President and
Chief Operating Officer of Syndax Pharmaceuticals, Inc., a publicly
traded oncology biopharmaceutical company.

I am extremely pleased to have Michael join our board. He will be a
valuable addition as we have made the transition to a clinical stage
company and are preparing for future growth,” said Drew Fromkin,
President and Chief Executive Officer of Tarveda Therapeutics.
Michael’s broad experience as a business executive in the life sciences
industry and successful track record building companies through
transactions will be critical as we continue to advance our internal
pipeline, initiate new collaborations and optimally finance our company.”

Mr. Metzger has served as President and Chief Operating Officer of
Syndax Pharmaceuticals, Inc. since May 2015. Prior to joining Syndax,
Mr. Metzger served as President and Chief Executive Officer of Regado
Biosciences, Inc., a publicly traded biotechnology company, where he
oversaw the company’s successful merger with Tobira Therapeutics, Inc in
2015. He also acted as an advisor to Tobira during its subsequent sale
to Allergan in 2016. Prior to that, Mr. Metzger served as Executive Vice
President and Chief Operating Officer at Mersana Therapeutics and led
mergers and acquisitions while in senior business development positions
at Forest Laboratories, Inc. Mr. Metzger also served as Vice President,
Corporate Development at Onconova Therapeutics, Inc. and was a managing
director at MESA Partners, Inc., a venture capital firm. Mr. Metzger
holds a B.A. from George Washington University and an M.B.A. in Finance
from the New York University Stern School of Business.

Tarveda has made great progress to rapidly advance its Pentarin
programs and platform. Tarveda’s novel approach has the potential to
address the significant challenges seen with earlier generations of drug
conjugates and improve the treatment options for patients with solid
tumors,” said Mr. Metzger. “I look forward to working with Tarveda’s
management team and my fellow board members to continue building Tarveda
into a success for the benefit of patients and shareholders.”

About Tarveda Therapeutics, Inc.
Tarveda Therapeutics, Inc.
discovers and develops Pentarins™, a new class of potent and selective
miniaturized drug conjugates with enhanced targeting capabilities for
the treatment of solid cancer tumors. Tarveda’s lead Pentarin drug
candidate, PEN-221, is a miniaturized drug conjugate that targets the
somatostatin receptor 2 (SSTR2) for treatment of patients with
neuroendocrine and small cell lung cancers. PEN-221 comprises a highly
selective peptide that targets SSTR2 linked to the potent cytotoxic DM1
through a cleavable linker. Tarveda is also advancing its HSP90 drug
conjugate platform with lead drug candidate PEN-866, which is a
miniaturized HSP90 targeting drug conjugate that comprises a small
molecule HSP90 targeting ligand conjugated to SN-38, the highly potent,
active metabolite of irinotecan. Tarveda’s strategy includes developing
its own proprietary Pentarins as well as applying the Pentarin platform
to enhance the effectiveness of the targeting moieties and novel
payloads of its pharmaceutical collaborators. www.tarveda.com


MacDougall Biomedical Communications
George MacDougall, 781-235-3060